Amended Current Report Filing (8-k/a)
December 21 2017 - 4:28PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 21, 2017
PROPHASE
LABS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-21617
|
|
23-2577138
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
file number)
|
|
(I.R.S.
Employer
Identification No.)
|
621
N. Shady Retreat Road, Doylestown, PA, 18901
(Address
of principal executive offices)
(Registrant’s
telephone number, including area code):
(215) 345-0919
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-2)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
December 21, 2017, ProPhase Labs, Inc. (“ProPhase”) issued a press release announcing the final results of its tender
offer for ProPhase common stock, which expired at midnight, New York City time, on December 18, 2017. That press release is filed
as Exhibit 99.1 hereto.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ProPhase
Labs, Inc.
|
|
|
|
By:
|
/s/
Ted Karkus
|
|
|
Ted
Karkus
|
|
|
Chairman
of the Board, Chief Executive Officer and Director
|
Date:
December 21, 2017
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Sep 2023 to Sep 2024